Mucopolysaccharidosis-Plus Syndrome.
Vasilev F, Sukhomyasova A, Otomo T.
Int J Mol Sci. 2020 Jan 9;21(2):421. doi: 10.3390/ijms21020421.
Characterization of heart disease in mucopolysaccharidosis type II mice.
Tavares AMV, Gonzalez EA, Viana IS, Visioli F, Vera LNP, Baldo G.
Cardiovasc Pathol. 2023 Nov-Dec;67:107575. doi: 10.1016/j.carpath.2023.107575. Epub 2023 Sep 18.
Glycosaminoglycans in mucopolysaccharidoses and other disorders.
Khan SA, Nidhi F, Leal AF, Celik B, Herreño-Pachón AM, Saikia S, Benincore-Flórez E, Ago Y, Tomatsu S.
Adv Clin Chem. 2024;122:1-52. doi: 10.1016/bs.acc.2024.06.011. Epub 2024 Jul 23.
Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland.
Żuber Z, Kieć-Wilk B, Kałużny Ł, Wierzba J, Tylki-Szymańska A.
Biomedicines. 2023 Jun 8;11(6):1668. doi: 10.3390/biomedicines11061668.
The Costello syndrome.
Say B, Güçsavaş M, Morgan H, York C.
Am J Med Genet. 1993 Aug 15;47(2):163-5. doi: 10.1002/ajmg.1320470203.
Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity.
Baldo G, Tavares AM, Gonzalez E, Poletto E, Mayer FQ, Matte UD, Giugliani R.
Cardiovasc Pathol. 2017 Mar-Apr;27:45-50. doi: 10.1016/j.carpath.2017.01.001. Epub 2017 Jan 6.
Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders.
Kleinboehl EW, Laoharawee K, Jensen JD, Peterson JJ, Slipek NJ, Wick BJ, Johnson MJ, Webber BR, Moriarity BS.
Mol Ther. 2024 Nov 6;32(11):3865-3878. doi: 10.1016/j.ymthe.2024.09.033. Epub 2024 Oct 4.
Emerging drugs for the treatment of mucopolysaccharidoses.
Giugliani R, Federhen A, Vairo F, Vanzella C, Pasqualim G, da Silva LM, Giugliani L, de Boer AP, de Souza CF, Matte U, Baldo G.
Expert Opin Emerg Drugs. 2016;21(1):9-26. doi: 10.1517/14728214.2016.1123690. Epub 2016 Jan 9.
Pre-operative Considerations in Adult Mucopolysaccharidosis Patients Planned for Cardiac Intervention.
Cross B, Stepien KM, Gadepalli C, Kharabish A, Woolfson P, Tol G, Jenkins P.
Front Cardiovasc Med. 2022 Apr 4;9:851016. doi: 10.3389/fcvm.2022.851016. eCollection 2022.
Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses.
Fachel FNS, Frâncio L, Poletto É, Schuh RS, Teixeira HF, Giugliani R, Baldo G, Matte U.
Adv Drug Deliv Rev. 2022 Dec;191:114616. doi: 10.1016/j.addr.2022.114616. Epub 2022 Nov 7.
